Clinical trialNCT03739814RecruitingPhase 2Interventional

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

SponsorNational Cancer Institute (NCI)Enrollment84B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug, called ozogamicin. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers ozogamicin to kill them. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving inotuzumab ozogamicin and blinatumomab with or without ponatinib may be effective in treating patients with newly diagnosed, recurrent or refractory CD22 positive B-lineage acute lymphoblastic leukemia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Matthew J Wieduwilt
Alliance for Clinical Trials in Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

277 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Centro Comprensivo de Cancer de Upr
San Juan, Puerto Rico
Luis J. Santos Reyes
Recruiting
San Juan City Hospital
San Juan, Puerto Rico
Luis J. Santos Reyes
Recruiting

United States

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
Active, not recruiting
Alaska Breast Care and Surgery Llc
Anchorage, Alaska, United States
Suspended
Alaska Oncology and Hematology Llc
Anchorage, Alaska, United States
Suspended
Alaska Women'S Cancer Care
Anchorage, Alaska, United States
Suspended
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States
Suspended
Anchorage Oncology Centre
Anchorage, Alaska, United States
Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska, United States
Suspended
Katmai Oncology Group
Anchorage, Alaska, United States
Suspended
Providence Alaska Medical Center
Anchorage, Alaska, United States
Suspended
Kingman Regional Medical Center
Kingman, Arizona, United States
Suspended
Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States
Suspended
Pcr Oncology
Arroyo Grande, California, United States
Suspended
Providence Saint Joseph Medical Center/disney Family Cancer Center
Burbank, California, United States
Suspended
Community Cancer Institute
Clovis, California, United States
Active, not recruiting
University Oncology Associates
Clovis, California, United States
Active, not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Ibrahim Aldoss →
Recruiting
Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Deepa Jeyakumar
Recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
James K. Mangan
Recruiting
Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
Deepa Jeyakumar
Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
Active, not recruiting
Beebe Medical Center
Lewes, Delaware, United States
Suspended
Beebe South Coastal Health Campus
Millville, Delaware, United States
Suspended
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Suspended
Delaware Clinical and Laboratory Physicians Pa
Newark, Delaware, United States
Suspended
Helen F Graham Cancer Center
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Medical Oncology Hematology Consultants Pa
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Beebe Health Campus
Rehoboth Beach, Delaware, United States
Suspended
Tidalhealth Nanticoke / Allen Cancer Center
Seaford, Delaware, United States
Suspended
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, United States
Suspended
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Kimberley Doucette
Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Suspended
Jupiter Medical Center
Jupiter, Florida, United States
Ryan H. Devine
Recruiting
Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
William G. Blum
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
William G. Blum
Recruiting
Saint Luke'S Cancer Institute - Boise
Boise, Idaho, United States
Suspended
Saint Luke'S Cancer Institute - Fruitland
Fruitland, Idaho, United States
Suspended
Saint Luke'S Cancer Institute - Meridian
Meridian, Idaho, United States
Suspended
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, United States
Christopher M. Reynolds
Recruiting

237 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Blinatumomab →Inotuzumab ozogamicin →Ponatinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 May 2019
Primary completion: 1 Feb 2027
Completion: 1 Feb 2027
Last update posted: 21 Aug 2026
Registered enrollment: 84
Registry id: NCT03739814

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.